Silver: Adding the Autoimmune Picture The Thyroid Premium Silver tier includes everything in Bronze plus thyroid antibodies (TPOAb and TgAb)

What we know: GI side effects are common but typically improve after 36 months No deaths or major safety signals through 80104 weeks across two large trials Metabolic improvements (glucose, blood pressure, lipids) are substantial and sustained Discontinuation rate: 11.3% in general obesity population (TRIUMPH-1) better than initially feared from TRIUMPH-4's 18.2% 104-week extension shows continued weight loss to 30.3% no plateau at 80 weeks What we don't know: Full 2-year safety dataset (pending publication) Whether dysesthesia resolves or persists long-term Cardiovascular outcomes (trial ongoing) Weight regain trajectory after stopping Very rare adverse events requiring broader use to detect The bottom line: Retatrutide offers superior weight loss compared to existing medications and TRIUMPH-1's 11.3% discontinuation rate suggests the tolerability picture is better than TRIUMPH-4's osteoarthritis cohort implied

This is crucial, given the strong link between MASH and cardiovascular, metabolic, and renal conditions, where semaglutide has already shown established health benefits. MASH is closely linked to metabolic risk factors like obesity, type 2 diabetes, and high blood pressure
Think of your brain's neurochemical system as a complex electrical grid
Optional: Glycerin, propanediol